Clinical trials with AKT inhibitors, such as ipatasertib and capivasertib, when combined with AR blockade, have demonstrated modest benefits, particularly in PTEN-deficient prostate cancers; however, adverse effects like hyperglycemia and dermatological toxicities limit the therapeutic window [151]. This evidence concerns the gene PTEN and prostate carcinoma.